EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas

Danielle Algranati, Roni Oren iD, Bareket Dassa, Liat Fellus-Alyagor, Alexander Plotnikov, Haim Barr, Alon Harmelin, Nir London, Guy Ron iD, Noa Furth iD, Efrat Shema iD

eLife · 2024

DOI: 10.7554/elife.96257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Danielle Algranati und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel. Hauptthemen laut MEDLINE: Glioma, Histone Deacetylases, Histones, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, The Israel Science Foundation, Emerson Collective.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse midline gliomas (DMGs) are aggressive and fatal pediatric tumors of the central nervous system that are highly resistant to treatments. Lysine to methionine substitution of residue 27 on histone H3 (H3-K27M) is a driver mutation in DMGs, reshaping the epigenetic landscape of these cells to promote tumorigenesis. H3-K27M gliomas are characterized by deregulation of histone acetylation and methylation pathways, as well as the oncogenic MYC pathway. In search of effective treatment, we examined the therapeutic potential of dual targeting of histone deacetylases (HDACs) and MYC in these tumors. Treatment of H3-K27M patient-derived cells with Sulfopin, an inhibitor shown to block MYC-driven tumors in vivo, in combination with the HDAC inhibitor Vorinostat, resulted in substantial decrease in cell viability. Moreover, transcriptome and epigenome profiling revealed synergistic effect of this drug combination in downregulation of prominent oncogenic pathways such as mTOR. Finally, in vivo studies of patient-derived orthotopic xenograft models showed significant tumor growth reduction in mice treated with the drug combination. These results highlight the combined treatment with PIN1 and HDAC inhibitors as a promising therapeutic approach for these aggressive tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaHistone DeacetylasesHistonesHistone Deacetylase InhibitorsHumansAnimalsMiceProto-Oncogene Proteins c-mycVorinostatAntineoplastic AgentsCell SurvivalCell Line, TumorChildDisease Models, AnimalXenograft Model Antitumor Assays

Stichwörter der Autor:innen

DMGcancer biologyepigeneticshumanoncogene

Substanzen

Histone DeacetylasesHistonesHistone Deacetylase InhibitorsProto-Oncogene Proteins c-mycVorinostatAntineoplastic AgentsMYC protein, human

Autor:innen und Institutionen

  • Department of Immunology and Regenerative Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
  • Bioinformatics Unit, Department of Life Sciences Core Facilities, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.
  • Wohl Institute for Drug Discovery of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
  • Department of Chemical and Structural Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Racah Institute of Physics, Hebrew University, Jerusalem, Israel.

ORCID-Profile: Roni Oren, Guy Ron, Noa Furth, Efrat Shema

Förderung

  • European Research Council
  • The Israel Science Foundation
  • Emerson Collective
  • The Israeli Cancer Research Fund

Zitieren

APA

Algranati, D., Oren, R., Dassa, B., Fellus-Alyagor, L., Plotnikov, A., Barr, H., Harmelin, A., London, N., Ron, G., Furth, N., & Shema, E. (2024). Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas. eLife. https://doi.org/10.7554/elife.96257

Vancouver

Algranati D, Oren R, Dassa B, Fellus-Alyagor L, Plotnikov A, Barr H, et al. Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas. eLife. 2024. doi:10.7554/elife.96257

BibTeX
@article{Algranati2024,
  author = {Algranati, Danielle and Oren, Roni and Dassa, Bareket and Fellus-Alyagor, Liat and Plotnikov, Alexander and Barr, Haim and Harmelin, Alon and London, Nir and Ron, Guy and Furth, Noa and Shema, Efrat},
  title = {Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.96257}
}
Kostenlos starten →